IL17A and systemic sclerosis: For others, results are not yet available, such as tibulizumab, a BAFF/IL17 bispecific antibody studied in phase 2 in subjects with RA and primary Sjogren's syndrome, which is now being investigated in systemic sclerosis, and MEDI7352, an IgG-like bispecific antibody targeting nerve growth factor and TNF for the treatment of painful osteoarthritis, or obexelimab (targeting CD19 and FcyRIIb) in phase 3 for IgG4-related disease.